Astellas Grows Oncology Portfolio With Ganymed Purchase
Astellas Pharma has acquired Ganymed Pharmaceuticals for an upfront cost of €422m to get access to the German firm's cancer antibody pipeline.
You may also be interested in...
Deal Watch: Jazz Breaks Into Immuno-Oncology Via Licensing Pact With Werewolf
AstraZeneca licenses bispecific cancer antibody candidate from Harbour Biomed. Regeneron seeks new approach to gene therapy delivery in deal with ViGeneron.
Biopharma Quarterly Dealmaking Statistics, Q4 2016
Biopharma companies closed out 2016 with $9.6 billion in financing, the strongest quarter of the year. M&A deals reached $12.2 billion in value, led by Lonza's takeover of Capsugel; most of the fourth quarter's largest partnerships were built around innovative platforms in antibodies, peptides and gene therapy.
Deal Watch: Genentech Out-Licenses PI3K Inhibitor To Novogen
The Australian firm also buys out Glioblast to add to its capabilities in brain cancer. Meanwhile, India’s Sun Pharmaceutical acquires Auven’s Ocular Technologies, and GlaxoSmithKline partners with Fimbrion in urinary tract infections and with Zai Lab in autoimmune disorders.